CIPROFLOXACIN AND DEXAMETHASONE
Clinical safety rating: caution
Chelates with divalent cations (antacids Ca2+ Fe2+) reducing absorption May enhance effects of warfarin Associated with tendonitis and tendon rupture.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication and transcription. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene synthesis.
| Metabolism | Ciprofloxacin undergoes hepatic metabolism via CYP1A2 to several metabolites (e.g., desethylciprofloxacin, sulfociprofloxacin). Dexamethasone is metabolized by CYP3A4 to 6β-hydroxydexamethasone and other metabolites. |
| Excretion | Ciprofloxacin: 50-70% unchanged in urine via glomerular filtration and tubular secretion; 20-35% in feces via biliary and intestinal secretion. Dexamethasone: primarily metabolized, <10% unchanged in urine; biliary/fecal excretion of metabolites. |
| Half-life | Ciprofloxacin: 3.7-4.3 hours (prolonged in renal impairment). Dexamethasone: 3-4 hours. |
| Protein binding | Ciprofloxacin: 20-40% bound to albumin. Dexamethasone: 77% bound to albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Ciprofloxacin: 2-3 L/kg (extensive tissue penetration). Dexamethasone: 0.8-1.0 L/kg. |
| Bioavailability | Ciprofloxacin: ophthalmic/otic ~90% (local, minimal systemic absorption). Dexamethasone: ophthalmic/otic <1% systemic absorption. |
| Onset of Action | Otic: symptomatic relief within 24 hours. Ophthalmic: clinical effect within 1-2 days. |
| Duration of Action | Otic: administer twice daily for 7 days; clinical response within 48-72 hours. Ophthalmic: continue for 7-14 days; taper if prolonged use. |
4 drops into affected ear(s) twice daily for 7 days. Otic suspension; shake well before use.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No specific dose adjustment needed. Use with caution in severe renal impairment (CrCl <30 mL/min) due to potential ciprofloxacin accumulation; monitor for adverse effects. |
| Liver impairment | No specific dose adjustment needed for Child-Pugh A or B. For severe hepatic impairment (Child-Pugh C), use with caution and monitor for adverse effects. |
| Pediatric use | Children ≥6 months: 4 drops into affected ear(s) twice daily for 7 days. Do not use in neonates <28 days due to risk of adverse events. |
| Geriatric use | No specific dose adjustment; use with caution due to increased risk of adverse effects (e.g., tendonitis, neuropathy). Monitor renal function and hearing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Chelates with divalent cations (antacids Ca2+ Fe2+) reducing absorption May enhance effects of warfarin Associated with tendonitis and tendon rupture.
| FDA category | Animal |
| Breastfeeding | Ciprofloxacin: M/P ratio ~0.95; excreted into breast milk; potential for joint damage in nursing infants. Dexamethasone: M/P ratio unknown; significant excretion likely. Avoid breastfeeding if possible; if used, monitor infant for diarrhea, candidiasis, growth suppression. |
| Teratogenic Risk |
■ FDA Black Box Warning
Fluoroquinolones, including ciprofloxacin, are associated with an increased risk of tendinitis and tendon rupture, especially in patients >60 years, those on corticosteroids, and organ transplant recipients. Use should be reserved for conditions with no alternative therapy.
| Common Effects | Nausea |
| Serious Effects |
["Hypersensitivity to ciprofloxacin, other fluoroquinolones, or dexamethasone","Concurrent use with tizanidine (ciprofloxacin interaction)","Systemic fluoroquinolone use in tendinitis/tendon rupture history","Topical otic use with perforated tympanic membrane (risk of ototoxicity)"]
| Precautions | ["Tendinitis and tendon rupture","Peripheral neuropathy","Central nervous system effects (e.g., dizziness, seizures)","Exacerbation of myasthenia gravis","Clostridioides difficile-associated diarrhea","Photosensitivity","Hypersensitivity reactions"] |
Loading safety data…
| First trimester: Ciprofloxacin (FDA category C) associated with arthropathy in juvenile animals; dexamethasone (FDA category C) associated with cleft palate in animal studies. Inadequate human data. Avoid if alternatives exist. Second/third trimesters: Ciprofloxacin not associated with major malformations but may cause fetal cartilage damage; dexamethasone may cause intrauterine growth restriction, adrenal suppression. Weigh risks vs benefits. |
| Fetal Monitoring | Monitor maternal renal and hepatic function; fetal growth ultrasound; consider amniotic fluid index if prolonged use. Monitor neonate for adrenal suppression if dexamethasone used near term. |
| Fertility Effects | Ciprofloxacin: No known human fertility impairment. Dexamethasone: High doses may disrupt ovulatory cycles; effects reversible upon discontinuation. |